优化研究以加速儿童抗逆转录病毒药物及制剂的可及性
儿童抗逆转录病毒药物的研发过程漫长且远落后于成人药物开发。本文综述当前儿童抗逆转录病毒药物研发方法,并提出创新策略以简化、加速和更全面地开发最佳制剂。
要点
- 儿童抗逆转录病毒药物研发滞后于成人,需简化加速策略。
- 建议聚焦有限优先制剂、早期制定儿科研究计划并加强合作。
核心结论
- 儿童抗逆转录病毒药物研发需简化、加速并采用更全面的策略以开发最佳制剂。
- 应借鉴HIV领域的经验推动结核和病毒性肝炎等其他疾病的儿童制剂研发。
研究设计与样本
- 本文为综述,回顾当前儿童抗逆转录病毒药物研发方法并提出创新建议。
主要发现
- 儿童抗逆转录病毒药物研发过程漫长且远落后于成人药物开发。
关键数值与推荐
- 建议聚焦有限数量的优先制剂。
- 建议加强现有合作以确保在药物开发早期制定儿科研究计划。
- 需建立更简化高效的研发机制并使融资机制更可持续。
临床怎么用
- 临床应关注儿童抗逆转录病毒药物的安全有效制剂的可及性。
- 推动儿科研究计划早期纳入药物开发流程以加速儿童用药获批。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Globally 1.8 million children are living with human immunodeficiency virus (HIV), yet only 51% of those eligible actually start treatment. Research and development (R&D) for pediatric antiretrovirals (ARVs) is a lengthy process and lags considerably behind drug development in adults. Providing safe, effective, and well-tolerated drugs for children remains critical to ensuring scale-up globally. We review current approaches to R&D for pediatric ARVs and suggest innovations to enable simplified, faster, and more comprehensive strategies to develop optimal formulations. Several approaches could be adopted, including focusing on a limited number of prioritized formulations and strengthening existing partnerships to ensure that pediatric investigation plans are developed early in the drug development process. Simplified and more efficient mechanisms to undertake R&D need to be put in place, and financing mechanisms must be made more sustainable. Lessons learned from HIV should be shared to support progress in developing pediatric formulations for other diseases, including tuberculosis and viral hepatitis.
引用
- Penazzato M, Gnanashanmugam D, Rojo P, et al. Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. Clin Infect Dis. 2017. PMID: 29190337. doi:10.1093/cid/cix194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。